# NRG-GY035 (NCT07198074)

> Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

No report yet. It can be ordered.

- Drugs tested: bevacizumab plus pembrolizumab; bevacizumab
- Indication: pMMR, TP53-mutated advanced or recurrent endometrial cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07198074
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Advanced Endometrial Carcinoma; Recurrent Endometrial Carcinoma
- Interventions: Bevacizumab; Biospecimen Collection; Carboplatin; Computed Tomography; Magnetic Resonance Imaging; Paclitaxel; Pembrolizumab
- Enrollment: 255
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on NRG-GY035 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 3
- X threads: 3
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nrg-gy035-nct07198074